Merit Medical Systems (NasdaqGS:MMSI) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAidan Lahey - Equity Research AssociateBrian G. Lloyd - Chief Legal Officer and Corporate SecretaryMartha Aronson - President and CEORaul Parra - CFO and TreasurerConference Call ParticipantsDavid Rescott - Director and Senior Research AnalystJason Bednar - Managing Director and Senior Research AnalystJayson Bedford - Managing Director and Senior AnalystJim Sidoti - Senior Equity AnalystJohn Young - ...

Alphatec (NasdaqGS:ATEC) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsBen Haynor - Managing Director of Medical Technology ResearchPat Miles - CEOTodd Koning - CFOConference Call ParticipantsMatthew Blackman - Research AnalystOperatorGood afternoon, everyone, and welcome to the webcast of ATEC's fourth quarter and full year 2025 financial results. We would like to remind everyone that participants on the call will make forward-looking statements. These statements are based on curr ...

Alphatec (NasdaqGS:ATEC) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker2Good afternoon, everyone, and welcome to the webcast of ATEC's fourth quarter and full year 2025 financial results. We would like to remind everyone that participants on the call will make forward-looking statements. These statements are based on current expectations and are subject to uncertainties that could cause actual results to differ materially. These uncertainties are detailed in documents filed regularly with the S ...

TransMedics Group (NasdaqGM:TMDX) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker9Good afternoon, and welcome to TransMedics' fourth quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Laine Morgan from the Gilmartin Group for a few introductory comments.Speaker ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Boston Scientific and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the ...

February 24, 2026 Q4 2025 Supplemental Financial Information Use of Non-GAAP Financial Measures Inogen has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three and twelve months ended December 31, 2025, and December 31, 2024, and for the fiscal year ended December 31, 2023. Management believes that these non-GAAP financial measures, taken in conjunction with U.S. GAAP financial measures, provide useful information for both management and investors b ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Zynex between February 25, 2021 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - February 24, 20 ...

Performance was anchored by strong results in Bone Growth Therapies (BGT) and U.S. Limb Reconstruction, alongside double-digit growth in Global Spine Fixation. Management successfully transitioned the Spine commercial channel, with the top 30 U.S. distributor partners now driving over 75% of net sales compared to less than 50% in early 2024. The 7D FLASH navigation system continues to serve as a key differentiator, with earnout customers exceeding purchase commitments by more than 50%, validating the ...

Achieved approximately 20% U.S. augmentation market share within one year of launch, a milestone management notes took previous entrants nearly a decade to reach. Performance is attributed to a 'super cycle' of innovation addressing decades of stagnant R&D in the breast aesthetics industry, specifically targeting unmet safety and aesthetic needs. Management identifies a 'new era of transparency' on social media as a primary demand driver, with patients increasingly requesting the Motiva brand by name ...

The acquisition of Nexus Medical is being leveraged through existing NICU sales channels, exceeding initial integration expectations.Profitability in 2025 was significantly obscured by tariff impacts, prompting a comprehensive internal cost containment and pricing strategy to protect margins.Surgical pain performance was hindered by slower-than-anticipated hospital implementation of the NOPAIN Act reimbursement, despite Avanos holding several approved devices.The Pain Management portfolio saw double-digit g ...